Latest news
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - StocktwitsStocktwits · Fri, 07 Aug 2026 18:34:48 GMTThis Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursda - BenzingaBenzinga · Thu, 06 Aug 2026 14:12:18 GMTImmuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 12:01:01 GMTImmuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingViewTradingView · Wed, 05 Aug 2026 11:43:03 GMTImmuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 11:43:00 GMTImmuneering Corporation Q2 Net Income USD -17 - MoomooMoomoo · Wed, 05 Aug 2026 11:30:01 GMTBlackRock, Inc. (NYSE: BLK) discloses 6.7% ownership in Immuneering Corp (IMRX) - Stock TitanStock Titan · Tue, 28 Jul 2026 20:46:22 GMT